![]() The method of claim 14, wherein the composition is administered in a daily dose of each of Phyllanthus emblica and Shilajit in a range of from about 3 mg to about 100 mg, and a daily dose of trivalent chromium in a range from about 200 mcg to about 500 mcg.ġ7. The method of claim 14, wherein the composition is administered in a daily dose of each of Phyllanthus emblica and Shilajit in a range of from about 3 mg to about 100 mg, and a daily dose of trivalent chromium in a range from about 100 mcg to about 1000 mcg.ġ6. A method of mitigating cardiovascular risk factors in an individual human or animal suffering from type 2 diabetes mellitus or with metabolic syndrome symptoms comprising administering to the individual in need thereof an effective amount of a composition comprising trivalent chromium, an extract of Phyllanthus emblica and Shilajit, wherein a blood lipid parameter is improved.ġ5. The method of claim 1, wherein the improved endothelial function includes a decrease of from about 3% to about 5% in reflective index (RI) in the individual.ġ4. The method of claim 1, wherein the improved endothelial function includes a decrease of from about 25% to about 55% in the blood level of high sensitivity C-reactive protein (hs-CRP) in the individual.ġ3. The method of claim 1, wherein the improved endothelial function includes a decrease of from about 10% to about 15% in the blood level of malondialdehyde (MDA) in the individual.ġ2. The method of claim 1, wherein the improved endothelial function includes an increase of from about 15% to about 20% in the blood level of glutathione (GSH) in the individual.ġ1. The method of claim 1, wherein the improved endothelial function includes an increase of from about 15% to about 30% in the blood level of nitric oxide (NO) in the individual.ġ0. The method of claim 1, wherein the composition is prepared using spray drying or freeze drying in such a manner that exposure to heat is minimized.ĩ. The method according to claim 1, wherein the Shilajit includes at least about 50% by weight fulvic acids (FAs), at least about 10% by weight dibenzo-α-pyrone chromoproteins, and at least about 0.3% by weight total dibenzo-α-pyrones (DBPs) based on the total weight of the composition.Ĩ. The method according to claim 4, wherein the low molecular weight hydrolyzable tannoids include emblicanin-A, emblicanin-B, punigluconin, and pedunculagin.ħ. The method according to claim 1, wherein the extract of Phyllanthus emblica includes greater than about 70% by weight low molecular weight hydrolyzable tannoids based on the total weight of the composition.Ħ. The method according to claim 1, wherein the extract of Phyllanthus emblica includes at least about 60% by weight low molecular weight hydrolyzable tannoids based on the total weight of the composition.ĥ. The method of claim 1, wherein the composition is administered in a daily dose of each of Phyllanthus emblica and Shilajit in a range of from about 3 mg to about 100 mg, and a daily dose of trivalent chromium in a range from about 200 mcg to about 500 mcg.Ĥ. ![]() The method of claim 1, wherein the composition is administered in a daily dose of each of Phyllanthus emblica and Shilajit in a range of from about 3 mg to about 100 mg, and a daily dose of trivalent chromium in a range from about 100 mcg to about 1000 mcg.ģ. ![]() A method of treating or preventing endothelial dysfunction in an individual human or animal suffering from type 2 diabetes mellitus or with metabolic syndrome symptoms comprising administering to the individual in need thereof an effective amount of a composition comprising trivalent chromium, an extract of Phyllanthus emblica and Shilajit, wherein endothelial function is improved.Ģ. ![]() Novel therapeutic processes for enhancing immunized states of vaccinated subjectsĬOMPOSITIONS FOR INHIBITING INTESTINAL IRON ABSORPTIONĪntifungal formulation containing Streptomyces s.p.p., method for preparing the composition and relevant useĪntibodies specifically binding PDE8A and PDE8Bġ. METHOD AND COMPOSITION FOR THE TREATMENT OF MODERATE TO SEVERE KERATOCONJUNCTIVITIS SICCAĮVALUATION OF PRESENCE OF AND VULNERABILITY TO ATRIAL FIBRILLATION AND OTHER INDICATIONS USING MATRIX METALLOPROTEINASE-BASED IMAGINGĮffervescent Acidified Rehydration Preparations HAIR FOLLICLE MESENCHYMAL STEM CELLS AND USE THEREOF Transparent Sunscreen Compositions and Use Thereof
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |